These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 33440869)

  • 1. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
    Yung Y; Lee E; Chu HT; Yip PK; Gill H
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.
    Mughal TI; Abdel-Wahab O; Rampal R; Mesa R; Koschmieder S; Levine R; Hehlmann R; Saglio G; Barbui T; Van Etten RA
    Leuk Lymphoma; 2016 Jul; 57(7):1517-26. PubMed ID: 27240645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
    Spivak JL
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):1-5. PubMed ID: 15190515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Mesa RA
    Int J Hematol; 2002 Aug; 76 Suppl 2():193-203. PubMed ID: 12430925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Blastic Crisis in a Patient with Unusual Primary Myelofibrosis Characteristics; A Case Report.
    Razmara Lak E; Sharifzadeh S; Ramzi M; Mokhtari M; Asadpouri R; Abedi E; Tamaddon G
    Cardiovasc Hematol Agents Med Chem; 2024; 22(2):240-245. PubMed ID: 37317905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myelogenous leukemia stem cells: What's new?
    Copland M
    Curr Hematol Malig Rep; 2009 Apr; 4(2):66-73. PubMed ID: 20425417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
    Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
    Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I
    Blood; 1995 Jun; 85(11):3257-63. PubMed ID: 7756658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.
    Jørgensen HG; Holyoake TL
    Hematol Oncol; 2001 Sep; 19(3):89-106. PubMed ID: 11574931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jak-2 positive myeloproliferative neoplasms.
    Muxí PJ; Oliver AC
    Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular pathogenesis of chronic myeloid leukemia].
    Sasaki K; Mitani K
    Nihon Rinsho; 2009 Oct; 67(10):1894-9. PubMed ID: 19860186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
    Moore S; Haylock DN; Lévesque JP; McDiarmid LA; Samels LM; To LB; Simmons PJ; Hughes TP
    Blood; 1998 Oct; 92(7):2461-70. PubMed ID: 9746786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
    Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
    Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib.
    Avilés-Vázquez S; Chávez-González A; Hidalgo-Miranda A; Moreno-Lorenzana D; Arriaga-Pizano L; Sandoval-Esquivel MÁ; Ayala-Sánchez M; Aguilar R; Alfaro-Ruiz L; Mayani H
    Cancer Med; 2017 Dec; 6(12):2942-2956. PubMed ID: 29030909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
    Bisen A; Claxton DF
    Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.